Trademark: 90106080
Word
YODA
Status
Dead
Status Code
605
Status Date
Monday, August 23, 2021
Serial Number
90106080
Mark Type
3000
Filing Date
Tuesday, August 11, 2020
Published for Opposition
Tuesday, July 20, 2021
Abandoned Date
Monday, August 23, 2021

Trademark Owner History
YODA PHARMACEUTICALS INC. - Owner At Publication

Classifications
5 Pharmaceutical preparations for the treatment of central nervous system disorders or diseases, namely, neurological illnesses, psychiatric illnesses, and neurodegenerative diseases; pharmaceutical preparations for the treatment of psychiatric, emotional and behavioral disorders, namely, depression, bi-polar disorder, anxiety, panic disorder, schizophrenia, schizoaffective disorder, positive syndrome, negative syndrome, mood and cognitive related symptoms of psychiatric illnesses, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD); pharmaceutical preparations for the treatment of brain injuries, namely, traumatic brain injury (TBI), brain ischemia, post-stroke recovery, post-hemorrhage recovery, reversible cerebral vasoconstriction syndrome, spinal cord injury, convulsion, epileptic seizures; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD); pharmaceutical preparations for the treatment of loss of memory, cognition, or loss of neuronal functions associated with neurodegenerative diseases or aging; pharmaceutical preparations for the treatment of neurological diseases, namely, ataxia, sporadic or hereditary ataxias, cerebellar ataxia, parkinsonism ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), muscular dystrophy; pharmaceutical preparations for the treatment of neurodevelopmental disorders, namely, Tourette syndrome (TS), autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), developmental language disorder (DLD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of pain, namely, neuropathic pain; Pharmaceutical preparations for the treatment of inflammatory disorder or diseases, namely, inflammasome-related diseases, immunological diseases; pharmaceutical preparations for the treatment of auto-inflammatory diseases or auto-immune diseases, namely, multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), lupus, gout, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic inflammation, auto-inflammatory fever syndromes, cryopyrin-associated periodic syndromes (CAPS); pharmaceutical preparations for the treatment of liver-related inflammatory diseases, namely, chronic liver disease, non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis; pharmaceutical preparations for the treatment of kidney-related inflammatory diseases, namely, chronic kidney disease (CKD), hypertensive nephropathy, lupus nephritis, Type I diabetes, Type II diabetes, hemodialysis related inflammation; pharmaceutical preparations for the treatment of cardiovascular-related inflammatory diseases, namely, chronic heart disease (CHD), peripheral artery disease (PAD), hypertension, atherosclerosis, acute heart failure, systemic lupus erythematosus (SLE); pharmaceutical preparations for the treatment of neuroinflammation-related diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD), traumatic brain injury (TBI), brain ischemia, ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), muscular dystrophy, Tourette syndrome (TS), autism spectrum disorder (ASD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of age-related inflammatory degenerative diseases, namely, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), parkinsonism-dementia complex of Guam, atherosclerosis, osteoarthritis, neuronal cell death; Pharmaceutical drugs, namely, anti-inflammatory agents, antioxidants, antidepressants, antipsychotics, anti-Parkinson agents, central nervous system agents, stimulants, inhibitors, modulators, benzodiazepines, serotoninergic agents, dopaminergic agents, glutaminergic agents, analgesics, neuromuscular agents, and psychotherapeutic agents
The color(s) blue, red, white and green is/are claimed as a feature of the mark.
The mark consists of the stylized wording "YODA" in blue and the design of a side profile of a human head, with the head and neck thereof in white, brain thereof in green and blue, and white cerebral sulcus thereof in white, overlapping the letter "O". An incomplete oval in red is interwoven with the letters "YOD".

Trademark Events
Aug 24, 2021
Abandonment Notice E-Mailed - After Publication
Aug 23, 2021
Abandonment - After Publication
Aug 16, 2021
Teas Express Abandonment Received
Jul 20, 2021
Official Gazette Publication Confirmation E-Mailed
Jul 20, 2021
Published For Opposition
Jun 30, 2021
Notification Of Notice Of Publication E-Mailed
Jun 14, 2021
Approved For Pub - Principal Register
May 29, 2021
Teas/Email Correspondence Entered
May 28, 2021
Correspondence Received In Law Office
May 28, 2021
Teas Response To Office Action Received
Dec 7, 2020
Notification Of Non-Final Action E-Mailed
Dec 7, 2020
Non-Final Action E-Mailed
Dec 7, 2020
Non-Final Action Written
Dec 5, 2020
Assigned To Examiner
Sep 12, 2020
Notice Of Design Search Code E-Mailed
Sep 11, 2020
New Application Office Supplied Data Entered In Tram
Aug 14, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24